* Maximus, a Reston government contractor, said it earned $10.2 million (47 cents a share) in the three months ended Sept. 30, up from a profit of $9.4 million (44 cents) in the comparable quarter last year. The company's fourth-quarter revenue rose to $154 million from $153.2 million in the year-ago period. For the fiscal year, the company earned $38.8 million ($1.76) on $603.8 million in revenue, up from a $35.3 million ($1.66) profit on $558.3 million in revenue. Shares of Maximus rose 39 cents to close at $28.23.

* Convera, a Vienna software company, said it lost $4.5 million (13 cents a share) in the three months ended Oct. 31, compared with a $3.3 million (10 cents) loss in the comparable period last year. Revenue fell to $6.1 million from $8.7 million. Shares of Convera, which reported its results after markets closed, rose 10 cents to close at $4.38.

* SAIC of San Diego, which has major operations in McLean, won two contracts from the Space and Naval Warfare Systems Center to support Saudi Arabia's Royal Saudi Naval Forces' C4I (command, control, communications, computers and intelligence) system. SAIC is responsible for engineering, analysis, maintenance and training. The two contracts could be worth up to $195.7 million altogether over eight years. SAIC has provided services to the Royal Saudi Naval Forces since winning a systems integration contract in 1979.

* Lockheed Martin, a Bethesda defense contractor, won a $30 million contract to develop a test bed for the Army's Technology Integration Center program for the Comanche helicopter. The program focuses on developing open architecture that could reduce the cost of developing, building and equipping future military aircraft. Avionics, sensors and weapons are of particular concern in the contract.

* Analex, an Alexandria company that provides research, technology and intelligence services for defense projects, completed the sale of its Advanced Biosystems subsidiary, which develops medical defenses and treatments for biological weapons. Ken Alibek, vice chairman and chief scientist of Advanced Biosystems, is leading the management buyout, in which $1 million is being paid for 100 percent of the outstanding shares of the subsidiary.

* Guilford Pharmaceuticals of Baltimore named Dean J. Mitchell president and chief executive, effective Dec. 1. Mitchell is a 25-year veteran of the pharmaceutical industry and has held a number of senior management positions with Bristol-Myers Squibb and GlaxoSmithKline.

Compiled from reports by Washington Post staff writers.